Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day ...

Eli Lilly stock has been a big-time winner over the last couple of years, but looming tariffs are worrying some investors. The pharmaceutical sector could be the next industry to face sweeping ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.